Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759174 · ClinicalTrials.gov registry record
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
A clinical trial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- 673
- Enrollment target
NCT00759174 is a clinical trial that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 673 participants.
The verdict
NCT00759174 has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- 673 participants
- Enrollment target
Study Summary
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
Interventions
- DRUG No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759174
The ClinicalTrials.gov registry entry for NCT00759174 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT00759174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759174 about?
NCT00759174 is a clinical study titled "A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION". The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
What is the current status of trial NCT00759174?
This trial is currently completed. The enrollment target is 673 participants. The study started on 2008-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00759174?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT00759174?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.